ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report issued to clients and investors on Saturday. The brokerage set a “buy” rating on the stock.

CDXC has been the topic of several other reports. LADENBURG THALM/SH SH upped their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of ChromaDex in a research note on Monday, March 17th.

ChromaDex Price Performance

ChromaDex has a 1 year low of $2.31 and a 1 year high of $9.18. The firm has a market cap of $611.50 million, a price-to-earnings ratio of 787.29 and a beta of 2.21. The business’s fifty day moving average is $6.16 and its 200 day moving average is $5.44.

Hedge Funds Weigh In On ChromaDex

A number of large investors have recently made changes to their positions in the company. USA Financial Formulas acquired a new position in ChromaDex in the 4th quarter valued at $25,000. State of Wyoming bought a new stake in shares of ChromaDex in the fourth quarter valued at about $39,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of ChromaDex in the fourth quarter valued at about $53,000. Truist Financial Corp bought a new position in ChromaDex during the fourth quarter worth about $54,000. Finally, FMR LLC acquired a new stake in ChromaDex in the 3rd quarter worth about $55,000. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.